LumiThera, Inc.
LumiThera develops light-based photobiomodulation devices for ophthalmology, including the Valeda Light Delivery System for people with dry age-related macular degeneration. Its devices are intended to help improve vision and slow vision loss.
Facts
- HQ
- Poulsbo, WA, US
- Sectors
- Medical devices, Healthcare, Ophthalmology
- Stage
- Series C
- Members see funding amounts. .
Is this your organization? Claim it
GeekWire's Top Tech Stories for Sept. 14, 2025: Amazon Ends Commingling, Apple Acquires WhyLabs, Seattle Mayoral Candidate Katie Wilson Discusses Tech and Taxes
The most popular tech stories on GeekWire for the week of Sept. 14, 2025, include Amazon ending its commingling policy, Seattle mayoral candidate Katie Wilson's views on taxes and tech, Apple acquiring Seattle startup WhyLabs, and several startup funding and leadership updates.
Alcon Acquires LumiThera, Developer of FDA-Authorized Valeda Vision Device for Dry AMD
Alcon has acquired LumiThera, the developer of the FDA-authorized Valeda Light Delivery System, a device that improves vision in dry age-related macular degeneration patients using photobiomodulation. LumiThera will spin off its diagnostic business into a new company named OpZira, Inc.
LumiThera raises $14M to complete LIGHTSITE III trial and pursue U.S. clearance for Valeda
LumiThera, a Poulsbo, Wash. medical device startup, raised $14 million to finish enrollment in its LIGHTSITE III U.S. trial and seek U.S. regulatory clearance for Valeda, a photobiomodulation device for dry age-related macular degeneration already approved in the EU.
See all 5 stories, episodes and videos about LumiThera, Inc..
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events